<DOC>
	<DOCNO>NCT00792350</DOCNO>
	<brief_summary>In international non-interventional post-marketing surveillance study want evaluate patient characteristic HCC patient well efficacy safety Sorafenib ( NexavarÂ® ) treatment daily-life treatment condition . Specifically investigated tumor status , prior and/ concomitant surgical , radiological drug treatment duration Sorafenib treatment .</brief_summary>
	<brief_title>INSIGHT - Post Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>In outpatient diagnosis hepatocellular carcinoma ( HCC ) decision take investigator prescribe Nexavar Exclusion criterion must read conjunction local product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Sorafenib</keyword>
</DOC>